James Hambro & Partners LLP Purchases 1,919 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• James Hambro & Partners increased its Thermo Fisher Scientific stake by 0.8%, purchasing 1,919 shares to hold 231,390 shares valued at approximately $156.3 million. The position represents about 5.4% of the firm's portfolio.
• Institutional investors own 89.23% of Thermo Fisher’s shares, while insiders own 0.33%. Company insiders sold 73,768 shares worth roughly $44.1 million over the past 90 days.
• Thermo Fisher shares recently traded at $678.39, down 1.7%, but remain near their 52-week high. The company beat quarterly earnings and revenue estimates, and analysts give the stock a “Moderate Buy” consensus rating with an average price target of $654.05.

James Hambro & Partners LLP grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 231,390 shares of the medical research company's stock after buying an additional 1,919 shares during the quarter. Thermo Fisher Scientific makes up about 5.4% of James Hambro & Partners LLP's investment portfolio, making the stock its 9th biggest position. James Hambro & Partners LLP owned 0.06% of Thermo Fisher Scientific worth $156,260,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of TMO. Bank OZK acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth $1,096,000. Ausdal Financial Partners Inc. bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at $456,000. BlackRock Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at $15,501,867,000. German American Bancorp Inc. bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $4,920,000. Finally, Parallax Volatility Advisers L.P. bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $814,000. Institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of the business's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of the company's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares of the company's stock, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 73,768 shares of company stock valued at $44,122,820. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Down 1.7%

Shares of Thermo Fisher Scientific stock traded down $11.61 on Monday, hitting $678.39. 972,382 shares of the company's stock traded hands, compared to its average volume of 2,248,104. The firm's 50-day moving average price is $637.32 and its two-hundred day moving average price is $548.58. The stock has a market capitalization of $250.83 billion, a PE ratio of 36.48, a price-to-earnings-growth ratio of 2.89 and a beta of 0.87. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $704.00. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the prior year, the business posted $4.28 EPS. The firm's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TMO has been the topic of several research reports. Piper Sandler started coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They set an "overweight" rating on the stock. UBS Group upgraded Thermo Fisher Scientific from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $540.00 to $730.00 in a research report on Tuesday, September 8th. Scotiabank initiated coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They set an "outperform" rating for the company. Stifel Nicolaus set a $650.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. Finally, Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Thursday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $654.05.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.